Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melaniq is a multi-ingredient nutraceutical supplement developed by Oxford Biolabs Ltd. (also known as L.R. Research) specifically formulated to support natural hair pigmentation and address the underlying causes of hair graying. The product's mechanism of action involves providing essential precursors and enzymatic cofactors required for melanogenesis, the process of melanin production in hair follicles. Key ingredients include L-tyrosine, a direct precursor to melanin, and copper, which serves as a vital cofactor for the enzyme tyrosinase. Additionally, Melaniq contains catalase, an enzyme that helps neutralize hydrogen peroxide—a metabolic byproduct known to accumulate in hair follicles and bleach hair from the inside out. The formulation is supplemented with vitamins such as biotin, B12, and D3 to support overall hair health. It is marketed as a non-pharmaceutical consumer product for individuals experiencing premature graying or looking to maintain their natural hair color.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Melaniq.